Internal Oligoguanidinium Transporter: Mercury-Free Scalable Synthesis, Improvement Of Cellular Localization, Endosomal Escape, Mitochondrial Localization, And Conjugation With Antisense Morpholino For Nanog Inhibition To Induce Chemosensitization Of Taxol In Mcf-7 Cells

A nontoxic delivery vehicle is essential for the therapeutic applications of antisense phosphorodiam idat emorpholino oligonucleotides (PM0s). Though guanidinium-rich or arginine-rich cellular transporter conjugated Vivo-PMO or PPM degrees has been developed for in vivo application, however, either their toxicity or stability has become an issue. Previously, we reported nonpeptidic internal guanidinium transporter (IGT) mediated delivery of PMO for gene silencing and got encouraging results. In this paper, we report the synthesis of IGT using a Hg-free method for scale up and N-terminal modification of IGT with a suitable hydrophobic or lipophilic group to improve the cell permeability, endosomal escape, and mitochondrial localization and to reduce toxicity in the MTT assay. For the delivery of PMO, IGT-PMO conjugate was synthesized to target NANOG in cells, a transcription factor required for cancer stem cell proliferation and embryonic development and is involved in many cancers. Our data shows IGT-PMO-facilitated NANOG inhibition, and thereby the prevention of EpCAM-N-Cadlierin-ITimentin axis mediated epithelial to mesenchymal transition (EMT) in MCF-7 cells. Moreover, unlike taxol, NANOG inhibition influences the expression of sternness factor c-Myc, Hh-Gli signaling proteins, other cancer related factors, and their respective phenotypes in cancer cells. To the best of our knowledge, this is the first report to illustrate that the IGT-PMO-mediated NANOG inhibition increases the therapeutic potential of taxol and induces G0-G1 arrest in cancer cells to prevent cancer progression. However, it warrants further investigation in other cancer cells and preclinical platforms.